Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones

(marketscreener.com) BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with T-ALL/T-LL Expected by Mid-2023 Regulatory Submissions Planned for BEAM-301 by Late 2023/Early 2024 and BEAM-302 in Early 2024 ...https://www.marketscreener.com/quote/stock/BEAM-THERAPEUTICS-INC-102685993/news/Beam-Therapeutics-Reports-Progress-Across-Base-Editing-Portfolio-and-Outlines-Key-Anticipated-Milest-42691061/?utm_medium=RSS&utm_content=20230109